4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress

29th - 30th October 2020 | ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD
CONFERENCE SPEAKERS
Advisors
Petter Bjorquist
Petter Bjorquist
CEO,
Verigraft


PhD in Biology/Biochemistry from Gothenburg University. 50 + publications in peer reviewed journals, several book chapters and patents. Ten years within AstraZeneca R&D in Cardiovascular Diseases, twelve years at Cellartis/Cellectis as VP Regenerative Medicine, responsible for e.g. the major collaboration with Novo Nordisk on development of a human embryonic stem cell derived beta cell treatment for diabetes. Also, responsible for development of human pluripotent stem cell derived cardiomyocytes and hepatocytes. As of February 2014, CEO of VERIGRAFT AB, a pioneering company within tissue engineering and advanced regenerative medicine for use in treatment of cardiovascular, neuronal and other diseases.


Fabio D'Agostino
Fabio D'Agostino
Venture Partner,
Claris Ventures


Dr. Fabio D’Agostino brings extensive experience in cell and gene therapy to Claris Ventures, where he recently joined as Venture Partner. In 2013, he joined the Parenteral Drug Association (PDA) Cell and Gene Task Force (members include executives from GSK, Novartis, Lonza, Johnson & Johnson, Adaptimmune, Takeda, Bluebird Bio) with the aim to develop a manufacturing control strategy for cell and gene based medicinal products. His areas of expertise also include Lean Six Sigma (IASSCTM Certified Black Belt). Fabio started his career at the medical device company Sorin Group (now LivaNova) after a BSc and a MSc with honours in Biomedical Engineering from the Polytechnic University of Turin (Italy). Later, he moved to Newcastle (UK) to take an Engineering Doctorate in Biopharmaceutical Process Development at Newcastle University. One of his main projects was the Multifactorial Analysis of Mesenchymal stem cell properties for storage and transportation.


Speakers
Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer,
MarketsandMarkets


Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.


Petter Bjorquist
Petter Bjorquist
CEO,
Verigraft


PhD in Biology/Biochemistry from Gothenburg University. 50 + publications in peer reviewed journals, several book chapters and patents. Ten years within AstraZeneca R&D in Cardiovascular Diseases, twelve years at Cellartis/Cellectis as VP Regenerative Medicine, responsible for e.g. the major collaboration with Novo Nordisk on development of a human embryonic stem cell derived beta cell treatment for diabetes. Also, responsible for development of human pluripotent stem cell derived cardiomyocytes and hepatocytes. As of February 2014, CEO of VERIGRAFT AB, a pioneering company within tissue engineering and advanced regenerative medicine for use in treatment of cardiovascular, neuronal and other diseases.


Ryan Guest
Ryan Guest
Director Cell Production,
Immetacyte Ltd


Ryan Guest is a Director Cell Production at Immetacyte Ltd (CTL). He has more than a decade of experience in the design, development and implementation of cGMP cell therapy manufacturing and two decades of experience of working in the field of adoptive T cell therapy (TIL, CAR, TCR). Ryan leads, Immetacyte’s partnerships with NHS partners, academic & industry in designing cell therapy manufacturing processes, QC & regulatory packages to deliver high quality cell based AT(I)MPs to enable healthcare organisations to treat patients. This has been based on Immetacyte’s early adoption in the design and implementation of clean room free technologies, back in 2010, enabling increased parallel cellular therapy product manufacturing. He also has a wealth of experience in designing and setting up sophisticated, state-of-the-art, PQS systems


Qasim Rafiq
Qasim Rafiq
Associate Professor, Cell & Gene Therapy Bioprocessing,
University College London


Dr Qasim Rafiq is an Associate Professor at University College London in Cell and Gene Therapy Bioprocessing. He is a multidisciplinary engineer working at the life science, engineering and commercial interfaces and his research focuses on the bioprocessing, automation and biomanufacture of ATMPs. He currently leads a research portfolio of >£3.5m and heads up the Cell and Gene Therapy Bioprocess Engineering group at UCL which includes 4 post-doctoral researchers and 11 PhD students. He is also Programme Director of a new Masters programme which is launching in September 2020 entitled “Manufacture and Commercialisation of Stem Cell and Gene Therapies”. He is both a Chartered Engineer (CEng) and Chartered Scientist (CSci) and sits on multiple scientific and engineering committees including the British Standards Institute (BSI) Biotechnology Committee, the IChemE Biochemical Engineering Subject Interest Group and the BIA’s Cell and Gene Therapy Advisory Committee.


John Bridgeman
John Bridgeman
Director of Cell Therapy Research,
Immetacyte Ltd


John undertook his PhD in 2004 under the supervision of Dr. David Gilham and Prof. Robert Hawkins at the University of Manchester. During this time his main interest was uncovering the signalling and molecular interactions of chimeric antigen receptors (CAR) and development of novel costimulatory CARs. In 2010 John moved to the labs of Prof. David Price and Prof. Andrew Sewell at Cardiff University where he focussed on T-cell receptor (TC         R) gene transfer, using it as a tool to understand biological phenomena such as alloreactivity and TCR cross-reactivity, as well as further developing adoptive cell therapy strategies. In 2013 he was awarded a Wellcome Trust/NISCHR ISSF research fellowship within the Institute of Infection and Immunity at Cardiff University studying cross-reactivity profiles of virus specific T-cells. John has been Director of Cell Therapy Research at Immetacyte (formally Cellular Therapeutics) since 2014


Elsa Abranches
Elsa Abranches
Acting Head, Division of Advanced Therapies Director,
UK Stem Cell Bank


Dr. Elsa Abranches has a PhD in Stem Cell Biotechnology and over 17 years of research expertise working in the pluripotent stem cell field. Since December 2015, Dr. Elsa has joined the UK Stem Cell Bank team and as of January 2019, she has been appointed as the Group Leader of the Section of Stem Cell Biology and Director of the UK Stem Cell Bank. Her primary focus is developing and delivering a programme of standardisation and research & development that assures the quality of both research and clinical grade human pluripotent stem cell lines.


Luca Crippa
Luca Crippa
Downstream Supervisor,
Molmed


Dr. Luca Crippa is downstream supervisor in MolMed Process Development unit. After obtaining his degree in Pharmaceutical Biotechnologies at the University of Milan, he worked several years as research biochemist in San Raffaele Scientific Institute, with particular focus on protein purification. He joined MolMed in 2012 as downstream specialist and is currently involved in the development, optimisation and industrialization of purification strategies for GMP-grade large scale productions of both lentiviral and retroviral vectors for cell and gene therapy.


David Gilham
David Gilham
Vice President Research & Development,
Celyad


David Gilham joined Celyad as Vice President, Research & Development and member of the Executive Management Committee in September, 2016. After completing his Ph.D studies under the supervision of Professor Roland Wolf at the University of Dundee, Scotland, David joined Professor Robert Hawkins at the University of Bristol in 1996 to work on engineered T cells for cancer therapy. The group moved to the Paterson Institute, University of Manchester in 1998 where the focus of work was on developing T cell therapy including CAR T cells and tumor infiltrating lymphocytes (TIL). Upon achieving the position of Reader, Group leader and Faculty member of the Manchester Cancer Research Centre, David moved into Industry in 2016 to continue exploring the development of CAR T cell therapy within a biotechnology company.


Marina Tarunina
Marina Tarunina
Research Director,
Plasticell Limited


Dr. Marina Tarunina, research director at Plasticell Ltd, is an experienced scientist with a broad knowledge across different aspects of stem cell therapy development and commercialisation. She plays a major role in driving Plasticell’s internal R&D and external scientific collaborations on stem cell technologies. She joined Plasticell 12 years ago and was involved in the development of Plasticell’s main technological platform CombiCult® and its multiple applications in different areas of stem cell biology. Prior to joining Plasticell she worked as senior scientist at Inpharmatica Ltd focusing on drug discovery in the therapeutic area of metabolic diseases. Her academic career includes postdoctoral fellowships at Ludwig Institute for Cancer Research and Marie Curie Research Institute where she conducted research on tumour suppressors and senescence.


Nick Meyers
Nick Meyers
VP Product Development,
Boyd Consultants Ltd


Dr. Meyers is an experienced drug developer with 22 years industry experience in pharma (SB/GSK, Daichi Sankyo), Biotech (Alizyme Therapeutics, Phytopharm) and Consultancy (PPD), prior to joining Boyds in 2016.  He has a track record of high-quality delivery, managing internal and out-sourced programs (small molecules, biologics and ATMPs) in multiple therapeutic areas, with expertise spanning many of the disciplines required for drug development, and promoting the importance of linking development with commercial strategy.  A key motivation for Dr. Meyers’ is to help start-ups and spinouts add value to their programs and bridge the gap until they achieve critical mass internally and developing long-term relationships with clients wishing to pursue a virtual development model.  Dr. Meyers’ industry career was preceded by post-doctoral research fellowships in molecular virology at the University of Cambridge and in the UK civil service, after gaining a Ph.D at Cranfield University of and undergraduate studies in Oxford.


Anders Lindahl
Anders Lindahl
Professor/Chief Physician,
University of Gothenburg


Anders Lindahl M.D., Ph.D. is professor in cartilage regeneration at the Institute of Biomedicine, University of Gothenburg, Sweden. He is the medical director of the hospital cell transplantation unit and is leading a research group focused on cartilage regeneration and osteoarthritis since 1992. His research on human chondrocytes commenced in 1985 and pioneered the use of autologous chondrocyte transplantation (ACT) for the treatment of cartilage defects. The study was published in New England Journal of Medicine (Brittberg, Lindahl et al. 1994) were he was the corresponding author and the article is one of the most cited in orthopedics. Over 2000 patients have subsequently been treated and several publications from the group demonstrate over 80% restored joint function after long term follow up (10 – 20 years. He has written over 130 articles in the field of chondrocyte regeneration and stem cells with over 12000 citations. He has received several awards for his work. 


Christiane Niederlaender
Christiane Niederlaender
Regulatory Consultant and Director,
AMBR Consulting


Christiane has spent 12+ years in medicines, tissue, cell and gene therapy regulation, last with the MHRA, where she worked for 8 years until August 2019 assessing all groups of biological medicines and managing the Biologicals Unit. She was the UK representative at the EMA committee for advanced therapies (CAT) and the Rapporteur/ Co-Rapporteur/ CMC assessor for several ATMPs. She acted as the Rapporteur for the EMA gene therapy guideline and was drafting group member for many other CAT guidelines. Prior to joining the MHRA, Christiane worked for the UK competent authority responsible for the European Tissues and Cells Directive as an assessor and inspector. She has a Ph.D. and research background in cell-signalling, cancer and stem cells and obtained a law degree in 2005. She has set up her own consultancy company in September 2019.


Fabio D'Agostino
Fabio D'Agostino
Venture Partner,
Claris Ventures


Dr. Fabio D’Agostino brings extensive experience in cell and gene therapy to Claris Ventures, where he recently joined as Venture Partner. In 2013, he joined the Parenteral Drug Association (PDA) Cell and Gene Task Force (members include executives from GSK, Novartis, Lonza, Johnson & Johnson, Adaptimmune, Takeda, Bluebird Bio) with the aim to develop a manufacturing control strategy for cell and gene based medicinal products. His areas of expertise also include Lean Six Sigma (IASSCTM Certified Black Belt). Fabio started his career at the medical device company Sorin Group (now LivaNova) after a BSc and a MSc with honours in Biomedical Engineering from the Polytechnic University of Turin (Italy). Later, he moved to Newcastle (UK) to take an Engineering Doctorate in Biopharmaceutical Process Development at Newcastle University. One of his main projects was the Multifactorial Analysis of Mesenchymal stem cell properties for storage and transportation.


Ivan Wall
Ivan Wall
Professor of Regenerative Medicine, Cell & Gene Therapy Bioprocessing,
Aston University


Ivan Wall is Professor of Regenerative Medicine, Cell and Gene Therapy Bioprocessing at Aston University in Birmingham, UK. He obtained his PhD in cell and molecular biology of wound healing from Cardiff University (2007) and subsequently took postdoctoral research posts at the Eastman Dental Institute and the Institute of Ophthalmology, both at University College London (UCL). He obtained his first academic post at UCL in the Department of Biochemical Engineering (2009-2017), progressing from Lecturer to Reader (Associate Professor) before taking up his current post.  His research interests span bioprocess and analytical development for advanced therapy products and have been enabled through numerous collaborations with academic and industry partners around the world. He has published 70 papers to date and has been a visiting professor at Dankook University in South Korea since 2010. With partners in the UK and Ireland he has recently established a Centre for Doctoral Training that focusses on technologies for advancing regenerative medicine.


Tristan Pritchard-Meaker
Tristan Pritchard-Meaker
,
Leiden University Medical Centre


Tristan Pritchard-Meaker a Business Development Manager at Leiden University Medical Centre. He is responsible for engaging collaborations and commercial projects. Tristan completed a Master’s degree in Biochemical Engineering at University College London (UCL) going on to work in pharmaceutical and biotechnology organisations including GSK, Isolagen, Jacob’s Engineering and Lonza. He returned to research becoming a stem cell scientist again at UCL working with embryonic stem cells and neural differentiation. Later returning to commercial organisations working as a Stem Cell Specialist at Miltenyi Biotec and Business Development Management positons at Axiogenesis and the Cell and Gene Therapy Catapult


Andrea Ducci
Andrea Ducci
Associate Professor,
UCL Mechanical Engineering


Andrea is an Associate Professor in the Mechanical Engineering Department of UCL, deputy-chair of the IChemE Fluid Mixing Process Subject Group and UK-delegate of the EFCE Working Party on Mixing. He graduated in Aerospace Engineering in the University of Pisa in 1999, and received his PhD from King’s College London in 2004. His research expertise lies in fluid and mixing dynamics and is applied to a broad range of flows of fundamental, industrial and healthcare relevance. The core of his research addresses the flow and mixing aspects in chemical and biochemical reactors, where a multi-scale approach is employed towards the creation of advanced engineering tools for improved scaling up/down strategies. A thorough understanding of the complex phenomena and interaction occurring between the flow/mixing scales and the growing cells is central to the future design and control of biological systems, and crucial to deliver impacts in the biopharmaceutical and chemical sectors.


Ohad Karneili
Ohad Karneili
Founder & CEO,
Adva Biotechnology


Founder and CEO of Adva Biotechnology a company developing a state of the art automated autologous manufacturing system. A well-known international expert in cell therapy with extensive knowledge of the industry. Dr Karnieli was the founder and President of Atvio Biotech, a leading Innovation center for cell and gene therapy. Former VP of Technology & Manufacturing at Pluristem Therapeutics, and the former VP medical device at Goji solutions. Dr Karnieli served as the chair of several industry committees such as the process & product development committee of the International Society for Cellular Therapies, expert member in the ISO TC276 Biotechnology standard committee and the former chair of the science and technology committee of the Alliance for Regenerative Medicine. Furthermore, Dr Karnieli serves as an advisor and board member to several of the lead cell therapy developing companies. Dr Karnieli earned his PhD on Cell and Gene Therapy in the Sackler School of Medicine of the Tel Aviv University. Furthermore, he holds an MBA from the Haifa University business management school.


Robert Thomas
Robert Thomas
Professor of Manufacturing, Cell and Gene Therapies,
Loughborough University


Rob Thomas is Professor in Manufacturing for Cell and Gene Therapies at Loughborough University. He leads a team developing the process science and technologies to enable manufacturing of cell based regenerative medicine therapies. The focus is efficient experimental design and data utilisation to maximise control and quantify risk in process development and manufacture whilst containing cost. Such developments are required for realisation of production processes that adhere to the ethos of Quality by Design. His team have progressed areas such as in vitro haematopoietic progenitor expansion, immunotherapy scale up, and red blood cell production amongst other to support the development of commercially viable processes.


Roystein Bulman
Roystein Bulman
European Applications Manager,
Nova Biomedical


Roystein Bulman, European Applications Manager. Formally working in mammalian cell culture process development, currently responsible for BioProfile applications at Nova Biomedical for the European territory. Over 12 years bioprocessing experience, specifically in cell culture analysis, automation and system validation


Phillip Nold
Phillip Nold
Application Specialist,
Eppendorf


After obtaining his diploma in Biology from the Karlsruher Institute of Technology (KIT), Dr. Philipp Nold successfully performed his PhD studies at the renowned University Hospital of Giessen and Marburg in Germany where he graduated in 2017. In his PhD studies he conducted research on the GMP-conform production of human mesenchymal stem-cells in bioreactors. Based on this work, utilization of these cells as a therapeutic agent was applied successfully. With this knowledge, he became an infield application and stem cell specialist for Eppendorf. In his lecture he will talk about the different parameters which you have to consider to successfully design and optimize your stem-cell production in stirred-tank bioreactors.


Stefano Baila
Stefano Baila
Director of Operations & Business Development,
Anemocyte


Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia. Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT. Stefano also worked as Industrialization Manager at Celyad where he led process development and automation efforts for CAR-T therapeutics. Now he serves as Director of Operation and Business Development for Anemocyte  


Janet Downie
Janet Downie
CEO ,
RoslinCT


Janet Downie is the CEO of RoslinCT a  leading cell and gene therapy CDMO based in Edinburgh, providing services internationally. Janet has over 25 years’ experience in biologics manufacturing and testing.  She was previously the COO for Roslin Cells Ltd and part of the original team that established the pluripotent stem cell business. She then went on to set up the contract manufacturing division prior to the establishment of RoslinCT.  Janet has held various leadership roles across both operations and quality including Inveresk Research, PPL Therapeutics and Charles River Laboratories.  She has always had a passion for business growth through delivering a quality service and a focus on patient safety.  Janet has been a key part of the cell and gene therapy industry in the UK and was a member of the UK Taskforce for ATMP Manufacturing.  She is also a member of the and the BIA Cell Therapy and Manufacturing Committees.